MS-20

PreclinicalSmall molecule

MMicrobio Co Ltd

MS-20 is one of 130 small molecule programs targeting Lung Cancer. It is currently in Preclinical.

Indications

Total Trials

Active Trials

129

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lung CancerActive, not recruiting

Pancreatic CancerActive, not recruiting

Ulcerative ColitisActive, not recruiting

Gut MicrobiotaCompleted

Lung CancerPreclinical

Active, not recruiting

Pancreatic CancerPreclinical

Active, not recruiting

Ulcerative ColitisPreclinical

Active, not recruiting

Gut MicrobiotaPreclinical

Completed

Competition

Competitive Landscape

335 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

Medrol

Pfizer

Preclinical

1 2

Byetta

AstraZeneca

Preclinical

1 3

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

1 4

Ayvakit Sprinkle

MMemorial Sloan Kettering Cancer Center

Preclinical

1 5

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 6

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 7

Active Comparator

Moderna

Preclinical

1 8

Sulfonylureas

Eli Lilly

Preclinical

1 9

Nano-Crystalline Megestrol Acetate

Changchun GeneScience Pharmaceutical Co., Ltd.

Preclinical

1 10

Concurrent Lenvatinib

TTrans Tasman Radiation Oncology Group

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hepatocellular Carcinoma1 trial

Evaluation of Quality of Life and Survival With MS-20 in Patient With Advanced Hepatocellular Carcinoma (FDA IND 74572)

Unknown status·MMicrobio Co Ltd·Phase 2·NCT00707681·60 enrolled

Ulcerative Colitis1 trial

MS-20 on Patients With Ulcerative Colitis(UC)

Recruiting·NNational Taiwan University Hospital·N/A·NCT04908644·40 enrolled

Pancreatic Cancer1 trial

MS-20 on Gut Microbiota and Risk/Severity of Cachexia in Pancreatic Cancer Patients

Unknown status·NNational Taiwan University Hospital·N/A·NCT04600154·40 enrolled

Lung Cancer1 trial

A Randomized, Placebo Controlled Study to Evaluate the Safety and Potential Efficacy of MS-20 in Combination with Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer

Completed·MMicrobio Co Ltd·N/A·NCT04909034·15 enrolled

Gut Microbiota1 trial

The Impact of MS-20 on Gut Microbiota Composition in Adult Individuals

Completed·MMicrobio Co Ltd·N/A·NCT04674839·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for MS-20. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MS-20 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MS-20. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Microbio Co Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: MMicrobio Co Ltd

MS-20

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hepatocellular Carcinoma1 trial

Ulcerative Colitis1 trial

Pancreatic Cancer1 trial

Lung Cancer1 trial

Gut Microbiota1 trial

References

Drug Info

Quick Facts

Related News